ReviewBritish journal of cancer2010
Does ocular treatment of uveal melanoma influence survival?
Review in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 106 citations in OpenAlex.
- Secondary extraocular extension of choroidal melanoma following primary photodynamic therapy.Eye (London, England) · 2026Article
- Independent validation of time to treatment as a prognostic factor in uveal melanoma.BMC cancer · 2026Article
- Higher AJCC stage at primary tumor diagnosis may predict shorter survival in metastatic uveal melanoma.Scientific reports · 2025Article
- Article
- Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period.Cancers · 2023Article
- Review
- The Effects of Oncological Treatment on Redox Balance in Patients with Uveal Melanoma.Diagnostics (Basel, Switzerland) · 2023Article
- Fear of cancer recurrence and adverse cancer treatment outcomes: predicting 2- to 5-year fear of recurrence from post-treatment symptoms and functional problems in uveal melanoma survivors.Journal of cancer survivorship : research and practice · 2023Article
- Advances in the Application of Nanomaterials to the Treatment of Melanoma.Pharmaceutics · 2022Review
- Long-term relative survival in uveal melanoma: a systematic review and meta-analysis.Communications medicine · 2022Article
- Advances in the treatment of intraocular malignancies: A literature review.Frontiers in medicine · 2022Review
- Trends in Uveal Melanoma Presentation and Survival During Five Decades: A Nationwide Survey of 3898 Swedish Patients.Frontiers in medicine · 2022Article
- Patients presenting with stage IV uveal melanoma: Lessons learned.Indian journal of ophthalmology · 2022Review
- No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.BMC cancer · 2021Observational
- Epidemiology of uveal melanoma in Brazil.International journal of retina and vitreous · 2020Article
- Article
- Constitutive expression of c-REL in uveal melanoma patients: correlation with clinicopathological parameters and patient outcome.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Article
- The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma.Oncotarget · 2020Article
- Reflections on a Health Psychology Service for Patients with Uveal Melanoma: The Challenge of Psychological Screening and Intervention When Distress is 'Normal'.Journal of clinical psychology in medical settings · 2019Article
- Uveal melanoma-associated survival in Scotland.Eye (London, England) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of uveal (intraocular) melanoma is aimed at prolonging life, if possible conserving the eye and useful vision. About 50% of patients develop fatal metastatic disease despite successful eradication of the primary intraocular tumour. The effect of ocular treatment on survival is unknown, because the same survival data from case series can be interpreted in different ways. Treatment is therefore based on intuition and varies greatly between centres. Randomised trials of treatment vs non-treatment of asymptomatic tumours are desirable but would be controversial, difficult, expensive and possibly inconclusive. Strategies for coping with uncertainty are needed to avoid unethical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.